Comments
With its expertise in rabies vaccine production using the vero cell platform, public sector vaccine-maker Indian Immunologicals Ltd (IIL), an arm of the National Dairy Development Board (NDDB), is confident of starting Covaxin production by July/August as this vaccine uses the same technology, a top company official said.
The Centre is looking to accelerate production of the indigenous vaccine and has roped in IIL, Bharat Immunologicals & Biologicals Corporation (BIBCOL) and Haffkine Biopharmaceutical Corporation — to collectively provide 10-15 million doses a month by August-September.
‘See no challenge’
“We would need to repurpose our facilities. But we don’t see any big challenge to start Covid-19 vaccine production. The Covid-19 vaccine uses vero cell platform, which is what we use in our rabies vaccine. So, in terms of assimilation of technology, we don’t see any major challenge,” the official told BusinessLine .
He, however, refused to divulge further details about the quantity being planned for production and the probable revenue-sharing or royalty payments involved with the vaccine developers, Bharat Biotech and ICMR.
The indigenous inactivated vaccine is developed using Whole-Virion Inactivated Vero Cell derived platform technology. “We will make a few million doses a month,” the official informed.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.